Common Questions in Lipids 2010 Mehul Bhatt, MD Athens Heart Center.

Slides:



Advertisements
Similar presentations
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
Advertisements

Agents Used in the Treatment of Hyperlipidemia
Drugs in dyslipidaemias
Robert K Huff PharmD. Candidate May Objectives The study was designed to examine 3 main aspects Biochemical effects Safety Tolerability Evacetrapib.
Lipid Disorders and Management in Diabetes
Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Drugs and Dyslipidemias (statins and other lipid and atherosclerosis-modifying drugs) October 18, 2006 Frank F. Vincenzi.
Diagnosis and Treatment of Dyslipidemia  New guidelines are based on the “Adult Treatment Plan III (ATP III)” 2004  Focus = multiple risk factor assessment.
Dyslipidemia/Lipid management in Diabetes. M ECHANISMS R ELATING I NSULIN R ESISTANCE AND D YSLIPIDEMIA  TG  Apo B  VLDL (hepatic lipase) Kidney (CETP)CEHDL.
How Aggressive do we get on Lipids? Christopher Cannon, M.D. Senior Investigator, TIMI Study Group Cardiovascular Division, Brigham and Women’s Hospital,
Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum The Management.
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.
Drug Class Review Drug Effectiveness Review Project Marian McDonagh, PharmD Principal Investigator Statins and Fixed-dose Combination Products Containing.
ANTILIPEMICS LILLEY, READING & WORKBOOK: CHAP 28 Cardiovascular System.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 29 Antilipemic Drugs.
Role of Rosuvastatin in the Treatment of Dyslipidemia
1 LDL-C and CV Risk: What We Know and Don't Know Joseph J. Saseen, PharmD, FCCP, BCPS, CLS Associate Professor Clinical Pharmacy and Family Medicine University.
Understanding and Controlling Cholesterol
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 1 CHAPTER 29 Hypolipidemic Drugs.
Kirk Mykytyn, Ph.D. Department of Pharmacology
Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium sized arteries.
Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.
Hyperlipidemia Hyperlipoproteinemia Hyperlipoproteinemia (cholesterol, Triglyceride, LDL-C, VLDL) Lead to atherosclerosis and Coronary artery disease.
Nutrition & Heart Disease Key Concepts and Facts Heart disease is leading cause of death Dietary and lifestyle factors are important Diets that provide.
Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Step 3 P-treatment: Drug Class Selection. Pharmacological and Non- Pharmacological Management Dyslipidemia drug therapyLifestyle modification Smoking.
Chapter 19 Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium.
Niacin (Nicotinic Acid) C 6 H 5 NO 2. Nicotinamide- no reduction in blood cholesterol Inositol Hexaniacinate- not much research, unlikely that it lowers.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
The overwhelming case for LDL-C lowering
HYPERLIPIDEMIA Dan O’Connell, MD Montefiore Family Medicine August 2004.
HYPERLIPIDEMIA Applied Therapeutics Dr. Riyadh Mustafa Al-Salih.
BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 28 Antilipemic Drugs.
The IDEAL Cholesterol Christopher Cannon, M.D. TIMI Study Group Brigham and Women’s Hospital Cannon CP. JAMA 2005;294:
Chapter 21 Agents Used in the Treatment of Hyperlipidemia.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
 Define cholesterol.  Discuss the purpose of lipoproteins.  Distinguish between LDL and HDL.
Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome
CHOLESTEROL THE SILENT KILLER
Title slide.
Drugs for Lipid Disorders
By: Dr Israa Omar MBBS, MRCP, MSc pharmacology
Formative Test.
Intensive Statin Recommendations
AIM HIGH Niacin plus Statin to prevent vascular events
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
Oxford Niacin Trial.
FATS- Familial Atherosclerosis Treatment Study
Antilipidaemic agents
Back to the Basics of Dyslipidemia
The following slides highlight a report on a presentation at the Canadian Cardiovascular Congress held in Toronto, Ontario from October 24 to 29, 2003.
Cardiovascular System
Section 7: Aggressive vs moderate approach to lipid lowering
LRC-CPPT and MRFIT Content Points:
Major classes of drugs to reduce lipids
Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk  Terry.
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Case 1: A 78-year-old white female with hypertension and hyperlipidemia Discussion Points: In that this patient has documented atherosclerotic vascular.
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Section 6: Update on lipid treatment guidelines
Presentation transcript:

Common Questions in Lipids 2010 Mehul Bhatt, MD Athens Heart Center

Contemporary Guidelines (simple enough) National Cholesterol Education Program (NCEP) 2004 LDL < mg/dL for CAD and CAD-equivalent risk factors < mg/dL for 2+ CAD risk factors < 160 mg/dL for 0-1 CAD risk factor HDL > 40 mg/dL Triglycerides < 200 mg/dL

Contemporary Guidelines (simple enough) First: treat LDL... Second: HDL > Third: Triglyceride < 200

But…what are common lipid questions in 2010? NCEP guidelines lag behind contemporary lipidology Common issues: Best statin Coenzyme Q-10 NiacinEzetimibe Nutritional supplements

What is the best statin? 6 statins available 3 name-brand: atorvastatin (Lipitor™), fluvastatin (Lescol™), rosuvastatin (Crestor™) 3 generic: lovastatin (Mevacor™), pravastatin (Pravachol™), simvastatin (Zocor™) Efficacy of statins in reducing LDL and CV events undisputed Few head-to-head statin trials

What is the best statin? Potency Reduction in LDL at lower dose Achieve goal LDL < Linear decreasing LDL at higher dosages Rosuvastatin> Atorvastatin, Simvastatin> Fluvastatin, Lovastatin, Pravastatin From Cannon et al. NEJM 2001

What is the best statin? Best data in prevention of clinical events: PravastatinSimvastatinAtorvastatin Superior to low dose pravastatin MIRACL, PROVE-IT: improved clinical outcomes in the highest risk patients (during acute coronary syndromes) Rosuvastatin JUPITER: improved clinical outcome in low-risk patients with elevated CRP

What is the best statin? Prevention of cardiovascular events: From Cannon et al. NEJM 2001 and Ridker et al. NEJM 2008 PROVE-IT TIMI 22: Atovastatin superior to pravastatin after acute coronary syndromes JUPITER: Rosuvastatin prevents cardiovascular events in low risk patients

What is the best statin? Atherosclerotic plaque stabilization/regression: REVERSAL Trial 2004 (atorvastatin) ASTERIOD Trial 2006 (rosuvastatin) From Nissen et al. JAMA 2004

What is the best statin? Pleotropic effects Anti-inflammatory effects in atherosclerotic plaque Anti-thrombotic Improve endothelial function Increasing nitric oxide (vasodilator) Inhibits endothelin-1 (vasoconstrictor) Most data with high-dose atorvastatin and rosuvastatin Perhaps mediated through CRP and/or sCD40

What is the best statin? Pleotropic effects: High-dose atorvastatin and rosuvastatin have most proven effect on CRP in large trials From Ridker et al. NEJM 2005

What is the best statin? Summary: Benefits of statins undisputed More benefits in higher risk patients Acute coronary syndromes, high-CRP, multiple risk factors... Atorvastatin and Rosuvastatin: Most recent large trials Atherosclerotic plaque stabilization/regression data Are they better than less expensive alternatives? Or do they have more recent data?

Does Coenzyme-Q10 work? CoQ10 = Ubiquinone CoQ10: Fat-soluble compound found in hydrophobic portion of mitochondrial membrane Approx. 10% rate of statin related myalgia Statins reduce Co-Q10 levels 25-40% Depletion of skeletal muscle mitochondrial Co- Q10 may lead to myalgia and myopathy From Marcoff et al. JACC 2007

Does Coenzyme-Q10 work? Co-Q10 supplementation increases plasma level in patient taking statins Multiple observational and anecdotal reports of improvement in myalgia with Co-Q10 2 small randomized trials in patients with history of myalgia did show benefit Overall, Co-Q10 harmless, inexpensive, and may reduce statin-related myalgia

Niacin, revisited… Niacin used clinically in heart disease for over 50 years (pre-statin era) 1 st randomized controlled trial in lipids in CAD: Coronary Drug Project: Clofibrate and niacin in coronary heart disease. JAMA 1975; 8,341 males from years old with history of MI Randomized to conjugated estrogens, clofibrate, dextrothyroxine, niacin (3000 mg/day), or placebo Niacin had early reduction in rates of MI and a mortality benefit that was maintained at 15-year follow-up! From JAMA 1975 and Canner et al. JACC 1986

Niacin, revisited… Niacin = Nicotinic acid = Vitamin B3 In high doses decreases LDL, increases HDL Most common side effects are flushing, itching, rash Over-the-counter; relatively inexpensive Niacin extended-release tablets: available since 1997 (Niaspan) does reduce flushing rates NSAIDs 30 min before niacin and extended-release niacin are shown to reduce flushing

Niacin, revisited… ARBITER 6-HALTS CAD patients with LDL < 100, HDL < statin + extended-release niacin (2000 mg/day) - versus - - versus - statin + ezetimibe Lower LDL with ezetimibe Higher HDL and lower TG with niacin BUT OUTCOMES... From Taylor et al. NEJM 2009

Is there any value to ezetimibe? Ezetimibe (Zetia) Decreases intestinal absorption of cholesterol Effective in reducing LDL But, does not reduce plaque or clinical event Probably only useful when statins not toleratated

Nutritional supplement therapy SUPPLEMENTEFFECT Red yeast rice, Plantphytosterols and phytostanols (vegetable oil, nuts, legumes, whole grains) Reduce LDL Omega 3 fatty acids (fish oils, certain plants/nuts) Reduce TG, possibly raise HDL, possibly reduce CV event rates Green tea catechins and black tea theaflavins Possibly lower LDL Guggulipids, policosanol, cinnamon, garlic No effect

Summary Treat CAD and CAD-equivalent patients to LDL goal < “Best statin”: atorvastatin and rosuvastatin have most recent data with pleotrophic effects and plaque stabilization/regression Niacin has important role in lipid management Some quality nutritional supplement have value